Products for Research Use Only

EGFR-IN-182

CAT: 0804-HY-178955Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-178955Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
EGFR-IN-182 (Compound 4) is an EGFR inhibitor with an IC50 value of 199 nM. EGFR-IN-182 inhibits HSP90 and PI3K, with IC50 values of 5.007 and 13.596 μM respectively. EGFR-IN-182 exhibits strong anti-proliferative activity against MCF-7 and MDA-MB-231 cells. EGFR-IN-182 downregulates Cyclin D1, inducing cell cycle arrest; it enhances the activity of caspase-9, inducing cell apoptosis. EGFR-IN-182 downregulates the expressions of ERK and AKT. EGFR-IN-182 can be used for research on breast cancer[1].
Target
Akt; Apoptosis; Caspase; CDK; EGFR; ERK; HSP; PI3K
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
N1(CC2=CC=CC=C2)C3=NC(N/N=C/C4=NC(C=CC=C5)=C5N=C4)=NN=C3C6=C1C=CC=C6
Molecular Formula
C25H18N8
Molecular Weight
430.46
References & Citations
[1]Ezz-ElDien ES, et al. Design, synthesis, and antiproliferative efficacy of an innovative series of triazino[5,6-b]indole derivatives targeting EGFR, CD1, Hsp90, PI3K, and ERK/AKT as key molecular targets in cancer therapy. Eur J Med Chem. 2025 Oct 16;302 (Pt 1) :118263.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Akt; Caspase 9; EGFR/ErbB1/HER1; ERK; HSP90; PI3K